Searching for novel multimodal treatments in oligometastatic pancreatic cancer

BACKGROUND: Metastatic pancreatic cancer has a median overall survival of less than 12 months, even if treated with chemotherapy. Selected patients with oligometastatic disease could benefit from multimodal treatments connecting chemotherapy and surgical treatment or radiofrequency ablation (RFA) of...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Cancer
Auteurs principaux: Filippini, D. M., Grassi, E., Palloni, A., Carloni, R., Casadei, R., Ricci, C., Serra, C., Ercolani, G., Brandi, G., Di Marco, M.
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2020
Sujets:
Case Report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7106565/
https://ncbi.nlm.nih.gov/pubmed/32228504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-06718-3
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires